Literature DB >> 23543030

Persistence of Cushing's disease symptoms and comorbidities after surgical cure: a long-term, integral evaluation.

Ana Laura Espinosa-de-Los-Monteros1, Ernesto Sosa, Nayeli Martinez, Moisés Mercado.   

Abstract

OBJECTIVES: Successful surgery does not always resolve all the clinical consequences of hypercortisolism in patients with Cushing's disease (CD). Our purpose was to integrally evaluate a group of CD patients cured by pituitary surgery and look for the persistence of CD symptoms, signs, and comorbidities.
METHODS: We performed clinical and biochemical evaluations of 29 CD patients (2 males) cured by pituitary surgery. All patients underwent early (median 12 months) and late (median 58 months) postoperative evaluations. We sought information regarding hypercortisolism-related symptoms and signs, as well as metabolic, cardiovascular, reproductive, and psychologic comorbidities.
RESULTS: The prevalence of obesity dropped from 72.4% at diagnosis to 31% at early evaluation but increased again to 44.8% at the late evaluation. Diabetes was present in 14 patients (48.3%) at diagnosis and persisted in 9 at the late evaluation. Hypertriglyceridemia was present in 58.6% and 55.1% of patients at diagnosis and at the late follow-up, respectively. The prevalence of hypercholesterolemia was 79.3% at diagnosis, decreased to 55.1% at the early evaluation, and increased to 65.5% at the late evaluation. Menstrual abnormalities were originally present in 15 of 20 women, and 8 of the 15 had recovered normal periods when seen at the last evaluation. Among the 24 patients with depression at diagnosis, 11 and 6 still exhibited mood abnormalities at the early and late evaluations, respectively.
CONCLUSIONS: In a variable proportion of patients, the cardiovascular, metabolic, and emotional comorbidities of CD persist after long-term remission, irrespective of the initial degree of hypercortisolism.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23543030     DOI: 10.4158/EP12247.OR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  6 in total

Review 1.  Cushing's disease: the burden of illness.

Authors:  Rosario Pivonello; Maria Cristina De Martino; Monica De Leo; Chiara Simeoli; Annamaria Colao
Journal:  Endocrine       Date:  2016-05-17       Impact factor: 3.633

Review 2.  The Interaction of Insulin and Pituitary Hormone Syndromes.

Authors:  Marie Helene Schernthaner-Reiter; Peter Wolf; Greisa Vila; Anton Luger
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-28       Impact factor: 5.555

Review 3.  The risks of overlooking the diagnosis of secreting pituitary adenomas.

Authors:  Thierry Brue; Frederic Castinetti
Journal:  Orphanet J Rare Dis       Date:  2016-10-06       Impact factor: 4.123

4.  Identification of glucocorticoid-related molecular signature by whole blood methylome analysis.

Authors:  Roberta Armignacco; Anne Jouinot; Lucas Bouys; Amandine Septier; Thomas Lartigue; Mario Neou; Cassandra Gaspar; Karine Perlemoine; Leah Braun; Anna Riester; Fidéline Bonnet-Serrano; Anne Blanchard; Laurence Amar; Carla Scaroni; Filippo Ceccato; Gian Paolo Rossi; Tracy Ann Williams; Casper K Larsen; Stéphanie Allassonnière; Maria-Christina Zennaro; Felix Beuschlein; Martin Reincke; Jérôme Bertherat; Guillaume Assié
Journal:  Eur J Endocrinol       Date:  2022-01-13       Impact factor: 6.664

5.  Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension.

Authors:  Henry G Fein; T Brooks Vaughan; Harvey Kushner; David Cram; Dat Nguyen
Journal:  BMC Endocr Disord       Date:  2015-10-27       Impact factor: 2.763

Review 6.  Endocrine risk factors for COVID-19: Endogenous and exogenous glucocorticoid excess.

Authors:  Frederick Vogel; Martin Reincke
Journal:  Rev Endocr Metab Disord       Date:  2021-07-09       Impact factor: 6.514

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.